Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13862771 | 0.86 | TRPV1 (0.58) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25057020 | 0.86 | POLB (0.55) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL12598436 | 0.85 | SMN1; SMN2 (0.58) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL9853857 | 0.84 | POLB (0.56) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL19987536 | 0.83 | HSD17B10 (0.51) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13930929 | 0.83 | HSD17B10 (0.51) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL27917690 | 0.83 | SMN1; SMN2 (0.51) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL2705399 | 0.81 | CASR (0.44) | TRPV1TNFNOD1HDAC3HDAC1 | |
| SCHEMBL25056938 | 0.81 | POLB (0.54) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL19965725 | 0.80 | HSD17B10 (0.49) | TRPV1SMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | TRPV1 3047/4885SMN1; SMN2 3122/4885ALDH1A1 916/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | TRPV1 4786/4885SMN1; SMN2 1519/4885ALDH1A1 4701/4885 |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | RIPK1, RIPK3, RIPK2 | TRPV1 1335/4885SMN1; SMN2 1532/4885ALDH1A1 3976/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | TRPV1 1033/4885SMN1; SMN2 2631/4885ALDH1A1 2911/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | TRPV1 3480/4885SMN1; SMN2 2473/4885ALDH1A1 1182/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | TRPV1 843/4885SMN1; SMN2 4840/4885ALDH1A1 1892/4885 |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | TRPV1 1785/4885SMN1; SMN2 2921/4885ALDH1A1 607/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | TRPV1 3817/4885SMN1; SMN2 1987/4885ALDH1A1 2837/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | TRPV1 4229/4885SMN1; SMN2 4458/4885ALDH1A1 303/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | TRPV1 882/4885SMN1; SMN2 3321/4885ALDH1A1 3405/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | TRPV1 327/4885SMN1; SMN2 4860/4885ALDH1A1 2651/4885 |
| US-11673871-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | TRPV1 504/4885SMN1; SMN2 1846/4885ALDH1A1 81/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | TRPV1 2824/4885SMN1; SMN2 1710/4885ALDH1A1 142/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | TRPV1 1251/4885SMN1; SMN2 1954/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.